Fidelis Capital Partners LLC Purchases Shares of 22,280 CareDx, Inc. $CDNA

Fidelis Capital Partners LLC acquired a new stake in shares of CareDx, Inc. (NASDAQ:CDNA) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 22,280 shares of the company’s stock, valued at approximately $420,000.

A number of other hedge funds have also made changes to their positions in CDNA. Goldman Sachs Group Inc. increased its stake in shares of CareDx by 18.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock valued at $19,703,000 after acquiring an additional 170,504 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of CareDx by 11.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 133,966 shares of the company’s stock valued at $2,378,000 after acquiring an additional 13,619 shares during the period. JPMorgan Chase & Co. increased its stake in shares of CareDx by 41.2% during the second quarter. JPMorgan Chase & Co. now owns 68,602 shares of the company’s stock valued at $1,340,000 after acquiring an additional 20,028 shares during the period. First Trust Advisors LP acquired a new position in shares of CareDx during the second quarter valued at approximately $1,822,000. Finally, Nebula Research & Development LLC bought a new stake in CareDx during the second quarter worth approximately $281,000.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Wells Fargo & Company lifted their price target on shares of CareDx from $18.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Wall Street Zen upgraded shares of CareDx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 3rd. BTIG Research lifted their price target on shares of CareDx from $26.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of CareDx in a research report on Wednesday. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $25.00.

Insider Activity

In related news, CEO John Walter Hanna, Jr. sold 10,282 shares of CareDx stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $21.12, for a total value of $217,155.84. Following the completion of the sale, the chief executive officer owned 676,475 shares of the company’s stock, valued at approximately $14,287,152. The trade was a 1.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.40% of the stock is owned by company insiders.

CareDx Stock Performance

CareDx stock opened at $22.82 on Friday. The company has a 50 day moving average price of $19.75 and a 200 day moving average price of $19.15. CareDx, Inc. has a 52 week low of $10.96 and a 52 week high of $23.24. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -142.63 and a beta of 2.49.

CareDx (NASDAQ:CDNA) last issued its earnings results on Tuesday, April 28th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.23. The company had revenue of $117.70 million during the quarter, compared to analyst estimates of $102.03 million. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The company’s revenue for the quarter was up 39.3% on a year-over-year basis. During the same quarter last year, the business posted $0.09 EPS. Equities analysts forecast that CareDx, Inc. will post 0.22 earnings per share for the current fiscal year.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non?invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post?transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor?derived cell?free DNA assay used primarily in kidney transplant monitoring.